Roth Capital Forecasts GeoVax Labs FY2029 Earnings

GeoVax Labs, Inc. (NASDAQ:GOVX) – Analysts at Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a research report issued on Friday, March 28th. Roth Capital analyst J. Aschoff forecasts that the company will earn $12.20 per share for the year. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.49. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $2.38 million.

Separately, D. Boral Capital reiterated a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research report on Friday. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $14.20.

GeoVax Labs Stock Down 12.6 %

GeoVax Labs stock opened at $1.11 on Monday. The stock has a market cap of $10.47 million, a price-to-earnings ratio of -0.20 and a beta of 3.06. The business has a 50-day simple moving average of $1.67 and a 200 day simple moving average of $2.13. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GOVX. Geode Capital Management LLC boosted its stake in shares of GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. Citadel Advisors LLC bought a new stake in GeoVax Labs in the fourth quarter worth $104,000. Virtu Financial LLC purchased a new stake in GeoVax Labs during the third quarter valued at about $97,000. Finally, Northern Trust Corp bought a new position in shares of GeoVax Labs during the fourth quarter valued at about $29,000. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.